Gisli G Einarsson
Overview
Explore the profile of Gisli G Einarsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alfahl Z, Einarsson G, Elborn J, Gilpin D, ONeill K, Ferguson K, et al.
Respir Med
. 2024 Dec;
236():107906.
PMID: 39643125
Background And Objective: This study explored the relationship between total bacterial density, airway microbiota composition and clinical parameters in bronchiectasis. We determined changes with time during clinical stability and following...
2.
Lee A, Carson S, Reyne M, Marshall A, Moody D, Allen D, et al.
Lancet Microbe
. 2024 Oct;
5(12):100933.
PMID: 39395428
Background: Influenza A viruses (IAVs) are significant pathogens of humans and other animals. Although endemic in humans and birds, novel IAV strains can emerge, jump species, and cause epidemics, like...
3.
Sloan C, Sherrard L, Einarsson G, Dupont L, van Koningsbruggen-Rietschel S, Simmonds N, et al.
J Cyst Fibros
. 2024 Feb;
23(3):499-505.
PMID: 38360460
Background: Prescribers have an increasing range of inhaled antimicrobial formulations to choose from when prescribing both eradication and chronic suppression regimens in cystic fibrosis (CF). This study aimed to investigate...
4.
Einarsson G, Sherrard L, Hatch J, Zorn B, Johnston E, McGettigan C, et al.
J Cyst Fibros
. 2023 Dec;
23(2):252-261.
PMID: 38158284
Background: Whether there is any benefit in integrating culture-independent molecular analysis of the lower airway microbiota of people with cystic fibrosis into clinical care is unclear. This study determined the...
5.
Houston C, Alkhatib A, Einarsson G, Tunney M, Taggart C, Downey D
Eur Respir J
. 2023 Dec;
63(2).
PMID: 38135443
Rationale: Pulmonary exacerbations are clinically impactful events that accelerate cystic fibrosis (CF) lung disease progression. The pathophysiological mechanisms underlying an increased frequency of pulmonary exacerbations have not been explored. Objectives:...
6.
Linden D, Guo-Parke H, McKelvey M, Einarsson G, Lee A, Fairley D, et al.
Chest
. 2023 Apr;
164(3):625-636.
PMID: 37011709
Background: Epstein-Barr virus (EBV) frequently is measured at high levels in COPD using sputum quantitative polymerase chain reaction, whereas airway immunohistochemistry analysis has shown EBV detection to be common in...
7.
Linden D, Einarsson G
Am J Respir Cell Mol Biol
. 2023 Feb;
68(5):467-469.
PMID: 36796087
No abstract available.
8.
Allen D, Einarsson G, Tunney M, Bell S
Anal Chem
. 2022 Jun;
94(26):9327-9335.
PMID: 35713672
SERS is currently being explored as a rapid method for identification of bacteria but variation in the experimental procedures has resulted in considerable variation in the spectra reported for a...
9.
Einarsson G, Vanaudenaerde B, Spence C, Lee A, Boon M, Verleden G, et al.
Front Cell Infect Microbiol
. 2022 Apr;
11:764585.
PMID: 35368453
To date, investigations of the microbiota in the lungs of people with Cystic Fibrosis (PWCF) have primarily focused on microbial community composition in luminal mucus, with fewer studies observing the...
10.
Keir H, Shoemark A, Dicker A, Perea L, Pollock J, Giam Y, et al.
Lancet Respir Med
. 2021 Feb;
9(8):873-884.
PMID: 33609487
Background: Bronchiectasis is predominantly a neutrophilic inflammatory disease. There are no established therapies that directly target neutrophilic inflammation because little is understood of the underlying mechanisms leading to severe disease....